ACM
CBAY

Asymmetry Capital Management’s Cymabay Therapeutics CBAY Stock Holding History

Asymmetry Capital Management’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-762,219
Closed -$1.13M – 40
2020
Q1 		$1.13M Buy
+762,219
New +$1.28M 1.23% 26

Other funds holding CBAY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Asymmetry Capital Management's CBAY Position: Q2 2020 in Review

Asymmetry Capital Management sold out of Cymabay Therapeutics (CBAY) in Q2 2020, closing a stake of 762,219 shares — an estimated $1.13M sold.

Asymmetry Capital Management first reported a position in CBAY in Q1 2020 and held it in 1 quarter. The position peaked at $1.13M in Q1 2020. 114 funds tracked by Wall St. Rank hold CBAY as of Q2 2020.

  • Asymmetry Capital Management reported no remaining Cymabay Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Asymmetry Capital Management sold 762,219 Cymabay Therapeutics shares in Q2 2020, an estimated $1.13M.
  • Asymmetry Capital Management first reported a position in Cymabay Therapeutics in Q1 2020 and held it in 1 quarter.
  • Asymmetry Capital Management's Cymabay Therapeutics position peaked at $1.13M in Q1 2020.
  • 114 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q2 2020.

Based on Asymmetry Capital Management's 13F filing for Q2 2020, filed 6 Aug 2020.